β-Eudesmol suppresses tumour growth through inhibition of tumour neovascularisation and tumour cell proliferation
Authors:
- 1 February 2008
- journal article
- research article
- Published by Taylor & Francis in Journal of Asian Natural Products Research
- Vol. 10 (2) , 159-167
Abstract
In the present study, we investigated the potential anti-angiogenic mechanism and anti-tumour activity of β-eudesmol using in vitro and in vivo experimental models. Proliferation of human umbilical vein endothelial cells (HUVEC) stimulated with vascular endothelial growth factor (VEGF, 30 ng/ml) and basic fibroblast growth factor (bFGF, 30 ng/ml) was significantly inhibited by β-eudesmol (50–100 μM). β-Eudesmol (100 μM) also blocked the phosphorylation of cAMP response element binding protein (CREB) induced by VEGF (30 ng/ml) in HUVEC. β-Eudesmol (10–100 μM) inhibited proliferation of HeLa, SGC-7901, and BEL-7402 tumour cells in a time- and dose-dependent manner. Moreover, β-eudesmol treatment (2.5–5 mg/kg) significantly inhibited growth of H22 and S180 mouse tumour in vivo. These results indicated that β-eudesmol inhibited angiogenesis by suppressing CREB activation in growth factor signalling pathway. This is the first study to demonstrate that β-eudesmol is an inhibitor of tumour growth.Keywords
This publication has 12 references indexed in Scilit:
- Antiangiogenic activity of β-eudesmol in vitro and in vivoEuropean Journal of Pharmacology, 2005
- Recent advances in angiogenesis, anti-angiogenesis and vascular targetingTrends in Pharmacological Sciences, 2002
- β-Eudesmol Induces Neurite Outgrowth in Rat Pheochromocytoma Cells Accompanied by an Activation of Mitogen-Activated Protein KinaseThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Mechanisms of normal and tumor-derived angiogenesisAmerican Journal of Physiology-Cell Physiology, 2002
- Angiogenesis: regulators and clinical applicationsBiochemical Pharmacology, 2001
- Vascular Endothelial Cell Growth Factor Activates CRE-binding Protein by Signaling through the KDR Receptor Tyrosine KinaseJournal of Biological Chemistry, 2001
- Angiogenesis in cancer and other diseasesNature, 2000
- Inhibitory Effects of Tetrandrine on Angiogenesis in Adjuvant-Induced Chronic Inflammation and Tube Formation of Vascular Endothelial Cells.Biological and Pharmaceutical Bulletin, 1998
- Functional Importance of Amino-terminal Domain of Shc for Interaction with Insulin and Epidermal Growth Factor Receptors in Phosphorylation-independent MannerJournal of Biological Chemistry, 1996
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995